Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where are AMGN shares going?Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.The business decision is the result of a strategic portfolio prioritization by Amgen.In June 2021, Amgen and Kyowa Kirin agreed to jointly develop and commercialize KH ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.’s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults.Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S.Yuvezzi is expected to be broadly commercially available in the U.S. in the second q ...

Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly cro... ...

Key Takeaways CNX, GPN, HRMY, and UHS meet strict value criteria, including low P/CF and solid financial health.Each company is projected to grow both sales and EPS in the current financial year.All four stocks carry a Value Score of A and show consistent positive earnings surprises.The U.S. stock market remained subdued yesterday. While the Dow Jones Industrial Average gained 0.11% (+55.96 points) to 49,071.56, the broader market faced downside pressure. The S&P 500 slipped 0.13% to 6,969.01, while the tec ...

Everyone loves a good comeback story, and that's especially true in markets where business cycles ebb and flow. Last year's winners frequently turn into this year's laggards, and we've already seen examples of that this month as software stocks plunge and memory stocks soar.Today, we'll look at five stocks with comeback potential in 2026. The theme connecting these five companies is their miserable performance in 2025, and the steps they've taken to prove investors wrong in 2026.Each stock is off to a hot s ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

HARRISBURG, Pa. (AP) — Drugmaker Eli Lilly and Co. (LLY) said Friday that it will build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments. Indianapolis-based Eli Lilly, maker of weight-loss treatment Zepbound and diabetes drug Mounjaro, is in the midst of a broader domestic expansion that includes new plants it has announced in Texas, Virginia and Alabama. Another facility is under construct ...

NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Theraepeutics Incorporated (NASDAQ: CORT)?Did you lose money in your investment in Corcept Theraepeutics Incorporated?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) violated federal securities laws. If you own Corcept stock and would lik ...

Key Takeaways SMMT's FDA-accepted BLA seeks approval of ivonescimab plus chemo for NSCLC after third-generation EGFR-TKIs.SMMT faces Nov. 14, 2026, PDUFA date, with FDA planning mid- and late-cycle reviews and labeling talks.SMMT's BLA is backed by the phase III HARMONi data that met PFS, while OS missed but trended favorably.Summit Therapeutics (SMMT) announced that the FDA has accepted its biologics license application (BLA) seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, ...

Key Takeaways Regeneron posted Q4 EPS of $11.44, beating estimates, while revenues rose 3% to $3.9 billion.REGN saw Eylea HD sales jump 66%, offsetting sharp declines in U.S. sales of its legacy Eylea drug.Higher R&D and manufacturing investments pressured margins, contributing to a 5% year-over-year EPS drop.Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $11.44, which comfortably beat the Zacks Consensus Estimate of $10.56. However, the bottom line ...